SHANGHAI YIZHONG(SH:688091) Xin Lang Cai Jing·2025-07-30 03:43Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi showed a turnover rate of 15.83%, with a trading volume of 35.2842 million yuan, indicating active market participation [3] - Over the past week, the Kexin Pharmaceutical ETF experienced a scale increase of 23.7936 million yuan, ranking first among comparable funds [3] - The ETF's net value increased by 59.34% over the past year, placing it in the top 10.34% of index equity funds [3] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including United Imaging Healthcare and BeiGene [5] - Notable stock performances include United Imaging Healthcare with a rise of 1.61% and BeiGene with a rise of 0.50% [5] Group 3: Policy and Market Trends - The National Healthcare Security Administration held a meeting to discuss policies supporting innovative drug development, emphasizing the use of healthcare data resources to support "true innovation" in drug development [6] - The focus is on encouraging pharmaceutical companies to expand the breadth and depth of innovation while avoiding excessive competition within the industry [6] Group 4: Market Outlook - Aijian Securities maintains a bullish outlook on the innovative drug sector, predicting a continued bull market in pharmaceutical technology for the year, with a focus on key areas such as ADC and dual antibodies [6] - Investors without stock accounts can access opportunities in the biopharmaceutical sector through the Kexin Pharmaceutical ETF Jiashi linked fund [7]